Spots Global Cancer Trial Database for everolimus (rad001)
Every month we try and update this database with for everolimus (rad001) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy | NCT01548807 | Prostate Cancer... | Everolimus (RAD... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) | NCT00790400 | Tuberous Sclero... Lymphangioleiom... | Everolimus (RAD... Everolimus Plac... | 18 Years - | Novartis | |
| Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer | NCT01152801 | Metastatic Rena... | Everolimus (RAD... | 18 Years - | Novartis | |
| 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer | NCT01626222 | Metastatic Brea... | Exemestane Everolimus (RAD... | 18 Years - | Novartis | |
| Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex | NCT00411619 | Tuberous Sclero... Subependymal Gi... | Everolimus | 3 Years - | Children's Hospital Medical Center, Cincinnati | |
| A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis | NCT01954693 | Tuberous Sclero... | Placebo Everolimus (RAD... | 16 Years - 60 Years | Cardiff University | |
| Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib | NCT01514448 | Metastatic Rena... | Everolimus (RAD... | 18 Years - | Novartis | |
| 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer | NCT01626222 | Metastatic Brea... | Exemestane Everolimus (RAD... | 18 Years - | Novartis | |
| An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1) | NCT01595009 | Neuroendocrine ... | Everolimus (RAD... | 18 Years - | Novartis | |
| Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer | NCT01152801 | Metastatic Rena... | Everolimus (RAD... | 18 Years - | Novartis | |
| A Trial of RAD001/Capecitabine in Refractory Gastric Cancer | NCT01099527 | Metastatic Gast... | Everolimus (RAD... Capecitabine | 18 Years - | Samsung Medical Center | |
| Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy | NCT00419159 | Colorectal Canc... | Everolimus (RAD... | 18 Years - | Novartis | |
| Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer | NCT00426530 | Breast Neoplasm... Neoplasm Metast... | everolimus (RAD... | 18 Years - | Novartis | |
| A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma | NCT00788060 | Renal Cell Carc... | Everolimus (RAD... Sunitinib (Sute... | 18 Years - | Duke University | |
| A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis | NCT01954693 | Tuberous Sclero... | Placebo Everolimus (RAD... | 16 Years - 60 Years | Cardiff University | |
| Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM) | NCT00792766 | Tuberous Sclero... Angiolipoma | everolimus (RAD... | 18 Years - 65 Years | Children's Hospital Medical Center, Cincinnati | |
| Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer | NCT01152801 | Metastatic Rena... | Everolimus (RAD... | 18 Years - | Novartis | |
| Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex | NCT00411619 | Tuberous Sclero... Subependymal Gi... | Everolimus | 3 Years - | Children's Hospital Medical Center, Cincinnati | |
| RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia | NCT00968253 | Leukemia Acute Lymphocyt... | Everolimus (RAD... Cyclophosphamid... Vincristine Doxorubicin Dexamethasone Mesna Methotrexate Ara-C (Cytarabi... Methylprednison... G-CSF | 10 Years - | M.D. Anderson Cancer Center | |
| Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy | NCT00419159 | Colorectal Canc... | Everolimus (RAD... | 18 Years - | Novartis | |
| 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer | NCT01626222 | Metastatic Brea... | Exemestane Everolimus (RAD... | 18 Years - | Novartis | |
| Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment. | NCT01022996 | Hodgkin Lymphom... | Everolimus (RAD... | 18 Years - | Novartis | |
| Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment. | NCT01022996 | Hodgkin Lymphom... | Everolimus (RAD... | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
